Directorio

This study has five parts: screening, treatment, end of treatment, safety check, and long-term follow-up. - Part A: People will try different amounts of a new medicine called KTX-2001 to find the safest dose. - Part B: People will take the best dose of KTX-2001 along with another medicine called darolutamide. KTX-2001 is taken on an empty stomach. Darolutamide is taken with food twice a day. You will get medicine to take at home and write down when you take it in a diary. You will have regular check-ups, scans, heart tests, and maybe a biopsy. After treatment, doctors will check on you for safety and follow up every few months until your cancer gets worse or you start a new treatment.

We are doing this study to learn more about how environmental contaminants (e.g., "forever chemicals") can affect people's likelihood of developing liver disease.

This study doesn't give any treatment. Instead, doctors will collect samples like blood, pee, spit, and a nose swab two times while you're in the hospital. Later, someone from the study will call you after 60 days to ask how you're feeling.

We are doing this study to see if the study drug, PT886, with or without chemotherapy and/or pembrolizumab, is a safe and effective option for gastric and pancreatic cancer. We are also trying to find the best dose of the study drug to use.

We are doing this study to see if the study drug, QTX3034, either with or without cetuximab, is safe and effective for treating KRAS G12D mutated cancer. We are also trying to find the best dose of QTX3034 to use.

We are doing this study to find out if an investigational drug called RMC-9805 (the study drug) is a safe and effective option for treating KRAS G12D mutated cancer. We are also trying to figure out what dose of the study drug works best for most people.

If you choose to join this study, you will:

• Get 2-6 cycles of Inotuzumab Ozagamicin, lasting 1 month per cycle
• Get Methotrexate on day one during cycle 1 and on day 28 of cycles 2, 4 and 6
• Get about 3-5 mL of blood collected prior to treatment and at three time points during cycle 1 and 4 time points during cycle 2

This study has three smaller parts called Sub Studies. In Sub Study 1, people receive a medicine called duvakitug. In Sub Study 2, people are placed by chance into one of three groups to receive duvakitug or a placebo. In Sub Study 3, people are placed by chance into one of two dose groups to receive duvakitug. The whole study lasts about 35 weeks and includes about 15 visits. During the visits, you will have heart tests, blood tests, an endoscopy with a biopsy, and questionnaires. When you join the study, you will be put into either Sub Study 1 or Sub Study 2. You will take the study medicine every two weeks for 12 weeks. After you finish Sub Study 1 or Sub Study 2, you may be asked to join Sub Study 3 to take duvakitug for another 12 weeks, or you may be asked to join another study called SUNSCAPE 2.